Drug Trial Radar · NCT06932471
Study of Safety and Efficacy of MY008211A in Patients With Residual Anemia Despite Anti-C5 Antibody Treatment
Last checked: Nov 20, 2026Latest source record: May 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Aug 30, 2024
Primary completion
Dec 30, 2025
Study completion Dec 30, 2025
Sponsor
- Lead sponsor
- Wuhan Createrna Science and Technology Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Apr 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to evaluate the efficacy of MY008211A in PNH patients with residual anemia despite treatment with anti-C5 antibody.
Conditions
- Paroxysmal Nocturnal Hemoglobinuria
Interventions
MY008211A tabletsDrug
MY008211A tablets Participants will receive MY008211A at a dose of 400 mg orally b.i.d
Primary outcomes
What the sponsor says the trial is designed to measure.
- The proportion of Participants With Sustained Hemoglobin Levels of ≥ 120 g/L in the Absence of Red Blood Cell Transfusions (defined as no red blood cell infusion after D14 to D168)Time frame: between Day 126 and Day 168
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking Union Medical College Hospital (PUMCH).
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.